High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology

Table 1 Clinical characteristics and BCL-2 expression for the training and validation cohorts.

	N	(%)	BCL-2 (mean ± SE)	p value*	N	(%)	BCL-2 (mean ± SE)	p value*
All	180	100			354	100
Age ^†	64.3 ± 0.8				62.3 ± 0.5
Sex
Male	92	51	44.3 ± 7.7	0.15	290	82	23.72 ± 2.6	0.16
Female	88	49	68.5 ± 15.2		42	12	32.29 ± 2
Missing	-				22	6
Stage
I	90	50	57.9 ± 11.6	0.39	107	30	30 ± 3.1	0.8
II	27	15	54.5 ± 21		90	25	30.1 ± 3.2
III	37	21	54.4 ± 21		95	27	32.5 ± 3.7
IV	16	9	18.7 ± 1.2		38	11	26.7 ± 5
Missing	10	5			24	7
Differentiation
High	12	7	27.1 ± 5.3	0.22	23	7	27.6 ± 5.4	0.11
Moderate	44	24	63 ± 18.7		138	39	26.32 ± 2
Low	70	40	39.9 ± 7.8		168	48	34.13 ± 3
Missing	54	29			25	6
Histology
Adenocarcinoma	111	62	41.9 ± 8.7	0.49	134	38	24.5 ± 2.2	0.07
Squamous cell carcinoma	37	21	57.9 ± 19.5		161	46	35 ± 2.8
Large cell carcinoma	11	6	85.5 ± 45		5	1	30.4 ± 11.2
Adenosquamous carcinoma	13	7	37.8 ± 18.4		4	1	25.1 ± 6.7
Giant cell carcinoma	-				17	5	27 ± 6.6
Various	8	4			10	3
Missing	-				23	6

Abbreviations: SE; standard error
*p is given for t-test for comparison of continuous BCL-2 AQUA scores between 2 groups and for Analysis of Variance (ANOVA) for comparisons among more than 3 groups
^†Mean value and standard error of the mean are displayed for age in both cohorts

ISSN: 1471-2407